A new PET scan neuroimaging technique measured drug-related reductions in the size of brain plaques thought to be responsible for the progression of Alzheimer's disease, a new study found.
The technique, known as ¹¹C-PiB PET, showed that the drug bapineuzumab reduced the amyloid-β deposits in the brains of patients with mild-to-moderate Alzheimer's disease by about 25% compared with placebo (mean difference in ¹¹C-PiB retention ratio change from baseline =–0.24; 95% CI –0.39 to –0.09; P=0.003).
The results were reported online in the March 1 issue of The Lancet Neurology. The study did not evaluate whether reduction in plaque size resulted in clinical improvement in patients' condition.
Continue Reading
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_b.png?x-id=b5c1f506-66f7-41ba-9727-94da39b1d368)
No comments:
Post a Comment